Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 3Qtrs Business Results
October 25, 2004
- Business Forecast
October 25, 2004
- Business Forecast
October 25, 2004
- WORLD NEWS IN BRIEF
October 25, 2004
- Criteria for Designating "Prescription Drugs" Proposed
October 18, 2004
- Meet the Leaders (37)
October 18, 2004
- BULLETIN
October 18, 2004
- HPB Presents Issues for Discussion on Drug Distribution Reform
October 18, 2004
- REGULATORY NEWS IN BRIEF
October 18, 2004
- Decision on "Mixed" Medical Care May Be Left to Prime Minister
October 18, 2004
- No. of Hospital Beds, Clinics with Beds Continue to Fall
October 18, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 18, 2004
- The 63rd Meeting of the Japanese Cancer Association
October 18, 2004
- BULLETIN
October 18, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 18, 2004
- EPMA Member Companies Report 9.8% Sales Growth in FY2003
October 18, 2004
- PRESS SEMINAR
October 18, 2004
- Survey Highlights Growing Awareness of GE Drugs: Sawai
October 18, 2004
- MONITOR
October 18, 2004
- Mr Morioka Calls For Mega-mergers of Domestic Firms
October 18, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…